GLP-1 also regulates lipid metabolism in BAT and white adipose tissue (WAT) through the brain-adipocyte axis [43,44]
The article points to patients with mobility limitations, severe obesity, cardiopulmonary comorbidities or arthritis, who it says may begin with GLP-1 monotherapy under provider supervision to reduce injury risk and build initial confidence
It is a sales claim unless backed by pharmacokinetic data (blood-level testing showing what is absorbed over time)
Leaner proteins digest faster, cause less nausea, and let you consume more total protein within your reduced appetite window
Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms
Current evidence suggests that the long-term safety profile of GLP-1 receptor agonists is favorable for most patients who tolerate therapy during the early phases of treatment